Cargando…

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Mostrar otras versiones (1)

BACKGROUND: Trastuzumab has recently shown efficacy in the treatment of HER2-positive advanced gastric adenocarcinoma. Although antibody-based therapies target the metastatic disease, HER2 status is usually evaluated in the primary tumour because metastatic sites are rarely biopsied. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bozzetti, C, Negri, F V, Lagrasta, C A, Crafa, P, Bassano, C, Tamagnini, I, Gardini, G, Nizzoli, R, Leonardi, F, Gasparro, D, Camisa, R, Capelli, S, Silini, E M, Ardizzoni, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101935/ https://www.ncbi.nlm.nih.gov/pubmed/21487407 http://dx.doi.org/10.1038/bjc.2011.121

Ejemplares similares

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
por: Bozzetti, C, et al.
Publicado: (2011)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy
por: Negri, F V, et al.
Publicado: (2008)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Emergence of a HER2-amplified clone during disease progression in an ALK-rearranged NSCLC patient treated with ALK-inhibitors: a case report
por: Minari, Roberta, et al.
Publicado: (2020)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method
por: Bozzetti, Cecilia, et al.
Publicado: (2015)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma
por: Romani, Antonello A, et al.
Publicado: (2007)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
por: Terragni, Rossella, et al.
Publicado: (2014)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
por: Zeppellini, Annalisa, et al.
Publicado: (2021)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US
por: Xie, Jipan, et al.
Publicado: (2015)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis
por: Pellegrino, Benedetta, et al.
Publicado: (2020)

Clampless off-pump coronary artery bypass prevents early post-operative neurologic injury compared to on-pump: a propensity score matched analysis
por: Bassano, C, et al.
Publicado: (2013)

Improving a Synechocystis-based photoautotrophic chassis through systematic genome mapping and validation of neutral sites
por: Pinto, Filipe, et al.
Publicado: (2015)

Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma
por: Maestroni, Umberto, et al.
Publicado: (2021)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower, Elyse E, et al.
Publicado: (2017)

EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer
por: Ye, Peng, et al.
Publicado: (2022)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Comparison of Her-2, EGFR and Cyclin D1 in Primary Breast Cancer and Paired Metastatic Lymph Nodes: An Immunohistochemical and Chromogenic In Situ Hybridization Study
por: Cho, Eun Yoon, et al.
Publicado: (2008)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Sunscreens, skin photobiology, and skin cancer: the need for UVA protection and evaluation of efficacy.
por: Gasparro, F P
Publicado: (2000)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
por: Harder, J, et al.
Publicado: (2012)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

High Prognostic Value of (68)Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
por: Gasparro, Donatello, et al.
Publicado: (2023)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vsc2gaohu1hjdh07svlon39vkl